Is the multinational, surveillance PRO-E2 study informative for all countries? The Italian data on VTE and contraceptive effectiveness

References

• de Leo V, Musacchio MC, Cappelli V, et al. Hormonal contraceptives: pharmacology tailored to women’s health. Hum Reprod Update. 2016;22(5):634–646. doi: 10.1093/humupd/dmw016.
   PubMed Web of Science ®Google Scholar
• de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813.
   PubMed Web of Science ®Google Scholar
• Lete I, Chabbert-Buffet N, Jamin C, et al. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review. Eur J Contracept Reprod Health Care. 2015;20(5):329–343. doi: 10.3109/13625187.2015.1050091.
   PubMed Web of Science ®Google Scholar
• Cagnacci A. Hormonal contraception: venous and arterial disease. Eur J Contracept Reprod Health Care. 2017;22(3):191–199. doi: 10.1080/13625187.2017.1305349.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24. doi: 10.1016/j.beem.2012.09.004.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Cagnacci A. Venous thrombosis and hormonal contraception: what’s new with estradiol-based hormonal contraceptives? Open Access J Contracept. 2018;9:75–79. doi: 10.2147/OAJC.S179673.
   PubMed Web of Science ®Google Scholar
• Bateson D, Butcher BE, Donovan C, et al. Risk of venous thromboembolism in women taking the combined oral contraceptive: a systematic review and meta-analysis. Aust Fam Physician. 2016;45:59–64.
   PubMed Web of Science ®Google Scholar
• Stegeman BH, De Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;347(sep12 1):f5298–f5298. doi: 10.1136/bmj.f5298.
   PubMedGoogle Scholar
• Dragoman M V, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287–294. doi: 10.1002/ijgo.12455.
   PubMed Web of Science ®Google Scholar
• Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin Drug Metab Toxicol. 2016;12(7):779–787. doi: 10.1080/17425255.2016.1190832.
   PubMed Web of Science ®Google Scholar
• Reed S, Koro C, DiBello J, et al. Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study. Eur J Contracept Reprod Health Care. 2021;26(6):447–453. doi: 10.1080/13625187.2021.1988923.
   PubMed Web of Science ®Google Scholar
• Reed S, Koro C, DiBello J, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care. 2021;26(6):439–446. doi: 10.1080/13625187.2021.1987410.
   PubMed Web of Science ®Google Scholar
• Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16(6):430–443. doi: 10.3109/13625187.2011.614029.
   PubMed Web of Science ®Google Scholar
• Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16(6):444–457. doi: 10.3109/13625187.2011.604450.
   PubMed Web of Science ®Google Scholar
• Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol: a double-blind, randomised study. Thromb Haemost. 2011;105(3):560–567. doi: 10.1160/TH10-05-0327.
   PubMed Web of Science ®Google Scholar
• von Stockum S, Bauerfeind A, Becker K, et al. NOMAC-E2 shows a better contraceptive effectiveness than LNG combined oral contraceptives in women under 25: real-world PRO-E2 study. Gynecol Endocrinol. 2023;39(1):2162036.
   Web of Science ®Google Scholar
• von Stockum S, Becker K, Bauerfeind A, et al. NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study. Gynecol Endocrinol. 2023;39(1):2166032.
   PubMed Web of Science ®Google Scholar
• Fabunmi OA, Dludla PV, Ngcobo SR, et al. Investigating the risks of cardiovascular disease among premenopausal women using oral contraceptive: a protocol for a systematic review and meta-analysis. BMJ Open. 2023;13(1):e071118. doi: 10.1136/bmjopen-2022-071118.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Farris M, Gallina Toschi A, et al. Overcoming barriers to oral contraception in Italy an expert opinion to empower women. Gynecol Endocrinol. 2023;39(1):2254400.
   PubMed Web of Science ®Google Scholar
• Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):344–354. doi: 10.1016/j.contraception.2006.12.019.
   PubMed Web of Science ®Google Scholar
• Bundesinstitut fur Arzneimittel und Medizinprodukte. 2022. Venose Thromboembolien und kombinierte Hormonale Kontrazeptiva. [Internet]. 2022. Available from: https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Themendossiers/Kombinierte-hormonale-Kontrazeptiva/KOK.html.
   Google Scholar
• Agenzia Italiana del Farmaco. 2021. Contraccettivi ormonali combinati: essere consapevoli del rischio di tromboembolia venosa tra i diversi medicinali, dell’importanza dei fattori di rischio individuali e vigilare sull’insorgenza dei segni e dei sintomi [Internet]. 2021. Available from: https://www.aifa.gov.it/documents/20142/1313724/2021.05.17_NII_contraccettivi_ormonali_combinati_IT.pdf.
   Google Scholar
• Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–339. doi: 10.1016/j.contraception.2016.06.010.
   PubMed Web of Science ®Google Scholar
• Grandi G, Facchinetti F, Bitzer J. Confirmation of the safety of combined oral contraceptives containing oestradiol on the risk of venous thromboembolism. Eur J Contracept Reprod Health Care. 2022;27(2):83–84. doi: 10.1080/13625187.2022.2029397.
   PubMed Web of Science ®Google Scholar
• Barnett C, Hagemann C, Dinger J, et al. Fertility and combined oral contraceptives–unintended pregnancies and planned pregnancies following oral contraceptive use–results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2017;22(1):17–23. doi: 10.1080/13625187.2016.1241991.
   PubMed Web of Science ®Google Scholar
• Barnett C, Dinger J, Minh TD, et al. Unintended pregnancy rates differ according to combined oral contraceptive–results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2019;24(4):247–250. doi: 10.1080/13625187.2019.1629412.
   PubMed Web of Science ®Google Scholar
• Dinger JC, Cronin M, Möhner S, et al. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol. 2009;201(3):263.e1-263–e9. doi: 10.1016/j.ajog.2009.03.017.
   Web of Science ®Google Scholar
• Dinger JC, Bardenheuer K, Assmann A. International active surveillance study of women taking oral contraceptives (INAS-OC study). BMC Med Res Methodol. 2009;9(1):77. doi: 10.1186/1471-2288-9-77.
   PubMedGoogle Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. [cited 2023 Oct 17]. Available from: https://www.who.int/publications/i/item/9789241549158.
   Google Scholar